Praluent (Alirocumab) Cost Reports: What People Actually Pay in 2026

Praluent is the brand name for alirocumab, a monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9) and is FDA-approved as an injectable add-on lipid-lowering therapy, given by prefilled pen every two weeks or monthly. It is not the same drug as evolocumab (Repatha) or inclisiran (Leqvio), which target the same pathway through different molecules and different mechanisms, and cost comparisons between them are discussed below.

Direct answer: Praluent's wholesale list price is commonly reported in the range of several thousand dollars per year, but list price is not what most insured patients pay. Commercially insured patients who qualify for the manufacturer copay program frequently report monthly costs of $0 to $150 after prior authorization; uninsured patients or those without assistance typically face several hundred dollars per month at retail. Medicare patients cannot use manufacturer copay cards by law, so their out-of-pocket exposure depends heavily on where they are in the Part D benefit phase and the 2025 annual out-of-pocket cap under the Inflation Reduction Act. These figures come from a mix of manufacturer program terms, payer coverage rules, and self-reported patient experience, not a controlled cost survey, and exact dollar amounts should be verified against your own plan documents and Sanofi's current program terms before you rely on them.

What this page can and cannot tell you

This is a cost-reporting page built from a mix of publicly available payer rules, manufacturer program structure, and patient self-report on forums such as Reddit and Drugs.com. Self-reported cost figures are useful for understanding the range and pattern of experience, but they are not a substitute for checking your own benefit design, and they cannot establish a reliable average cost because people with unusually good or unusually bad experiences post more often than people with routine, unremarkable ones.

The gap between list price and what people actually hand over

Praluent's wholesale acquisition cost is often cited in pricing databases and industry commentary, but net prices after manufacturer rebates to payers have reportedly fallen well below launch-era list price as PCSK9 inhibitor competition increased. That rebate-driven decline in net price does not automatically translate into a lower patient copay, because what a patient pays depends on formulary tier placement, deductible status, and whether the plan allows manufacturer copay assistance to count toward the deductible. Two patients on the same drug and the same insurer type can have very different bills depending on these plan-design details.

Reading through patient forum threads (r/cholesterol, r/FamilialHypercholesterolemia, r/HealthInsurance, Drugs.com reviews) shows a consistent split rather than a single "typical" number. Commercially insured patients who successfully enroll in copay assistance describe paying little to nothing. Patients on Medicare, or those still fighting a denial, describe costs that remain a real financial barrier. This is a pattern worth naming, but it is an observation from unverified, self-selected posts, not a study finding.

How insurance approval typically works

Most commercial and Medicare Part D plans require prior authorization for PCSK9 inhibitors. Typical payer criteria, consistent with cholesterol management guidance from cardiology professional societies, generally require documentation of a trial of statin therapy (or documented statin intolerance), concurrent use of maximally tolerated statin therapy where appropriate, and an LDL-C level above a plan-specific threshold. Guideline-based thresholds discussed in the cardiology literature commonly reference an LDL-C at or above roughly 70 mg/dL in patients with established atherosclerotic cardiovascular disease on maximal tolerated therapy, though your plan's specific cutoff may differ and should be confirmed with your prescriber's office.

Patient forum reports describe the approval process taking anywhere from a couple of weeks to several months, with first-round denials described as common, often because documentation of prior statin trials or LDL values was incomplete at first submission. Whether a prescriber's office has experience with specialty pharmacy prior authorizations appears, anecdotally, to affect how quickly approval happens, but this is an observed pattern from patient reports, not a controlled comparison.

An evidence-review framework: what counts as proof here

Cost and outcome claims about Praluent come from very different kinds of evidence, and mixing them together is the most common way this topic gets overstated. Use this table to sort any specific claim you read (here or elsewhere) before acting on it.

The general rule: patient self-report is good evidence of range and pattern of experience, randomized trial data is the strongest evidence of average clinical effect, and regulatory fact sheets are the strongest evidence of what a benefit rule actually is. None of these substitutes for the other, and a forum post cannot establish a cost average any more than a single trial's average effect predicts what happens to one specific patient.

What forum and review reports describe

Self-reported cost data clusters into a few recurring groups, though the underlying sample sizes on any single platform are small and skewed toward people motivated to post, whether because their experience was unusually good or unusually frustrating.

Commercially insured with copay assistance: the most frequently mentioned figure is $0 per month, attributed to enrollment in Sanofi's MyCarePath copay program after insurance approval. Some patients describe modest remaining copays in the $5 to $25 range.

Commercially insured without copay assistance: patients describe monthly costs roughly in the $75 to $300 range, with higher figures associated with percentage-based coinsurance on specialty drug tiers rather than a flat copay.

Medicare Part D: this is consistently described as the harder category, because manufacturer copay cards cannot legally subsidize Medicare cost-sharing. Patients describe higher costs earlier in the plan year before reaching the point where the annual out-of-pocket cap takes effect, after which costs for the remainder of the year drop substantially. The $2,000 annual Part D out-of-pocket cap took effect in 2025 under the Inflation Reduction Act and applies across covered Part D drugs, not to Praluent specifically (per federal regulatory guidance describing the Part D redesign; confirm current-year figures with CMS before quoting).

Uninsured at retail: patients and pharmacy-price-checking posts describe costs in the several-hundred-dollar-per-month range. Sanofi's Patient Connection program is reported to provide free drug to income-qualified uninsured patients; specific income thresholds should be confirmed directly with the program, as eligibility rules change.

Aggregate rating figures sometimes cited from consumer review sites (average scores across a small number of reviews) are not reproduced here as precise numbers, because small self-selected samples on a single site are not a reliable estimate of typical patient experience and the underlying counts are not independently verifiable at the time of this review.

Clinical evidence behind the cost conversation

The cost conversation only makes sense next to what the drug is shown to do. Alirocumab was studied in a large randomized cardiovascular outcomes trial in patients with recent acute coronary syndrome already on statin therapy, commonly referred to in the cardiology literature as ODYSSEY OUTCOMES, published in the New England Journal of Medicine in 2018. That trial is widely cited as showing a reduction in a composite of cardiovascular death, nonfatal myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization compared with placebo, with the largest absolute benefit reported in patients with higher baseline LDL-C. The exact event rates, hazard ratio, and confidence interval commonly quoted for this trial should be verified against the primary NEJM publication before being restated as precise figures in patient-facing material, since this draft could not confirm a verified primary-source link at the time of review.

Alirocumab's LDL-lowering effect in trials is generally described as substantial, often characterized as roughly a 50 to 60 percent reduction from baseline versus minimal change with placebo, though the exact percentage varies by dose, baseline LDL, and duration, and should also be confirmed against the primary trial publication rather than restated as a fixed number.

Reported adverse events in the outcomes trial are generally described as similar between alirocumab and placebo overall, with injection-site reactions somewhat more common with alirocumab. This is a commonly cited safety pattern for the drug class, but specific percentage rates require verification against the primary trial report.

What patients describe beyond cost

Beyond price, patient forum narratives describe two recurring themes. Some patients, particularly those who could not tolerate statins because of muscle symptoms, describe achieving target LDL levels on a PCSK9 inhibitor without recurrence of those symptoms, and describe this as a meaningful improvement in their treatment options. Others describe injection-site reactions, ongoing prior-authorization renewal burden, or muscle symptoms they attribute to the drug, though distinguishing a PCSK9 inhibitor effect from carryover statin-related symptoms is genuinely difficult in an uncontrolled, unblinded self-report.

No specific patient quotation from a review site is reproduced in this article, because individual testimonial quotes from anonymous online reviews cannot be independently verified and a fabricated or unverifiable quotation would be worse than none.

Praluent versus Repatha: how cost compares

Repatha (evolocumab) is the other FDA-approved PCSK9 inhibitor antibody, and it is commonly described in the cardiology literature as having broadly similar relative cardiovascular risk reduction and LDL-lowering effect to alirocumab, based on its own separate large outcomes trial (commonly referred to as FOURIER). Because efficacy is described as broadly comparable between the two drugs, the practical choice for many patients comes down to formulary placement, rebate-driven payer preference, and copay card terms rather than a meaningful clinical efficacy difference. Patient advocates on forums commonly recommend asking a prescriber's office to run a benefits investigation for both drugs before committing to one, since the drug a plan prefers can change from year to year.

Inclisiran (Leqvio) works through a different mechanism (small interfering RNA against PCSK9 mRNA, administered by a healthcare professional twice yearly rather than self-injected) and is not a biosimilar of alirocumab. Its cost structure, tied to a buy-and-bill administration model, is different enough from a self-administered specialty pharmacy drug that direct cost comparison requires checking your specific plan's medical versus pharmacy benefit rules.

Strategies patients describe for reducing cost

Patients who report the lowest out-of-pocket costs describe a consistent set of steps, though these are patterns from self-report, not a tested protocol:

• Submitting complete prior authorization documentation up front, including statin trial history, LDL values on maximally tolerated therapy, and relevant diagnosis codes, since incomplete documentation is frequently cited as the reason for first-round denial.
• Enrolling in the MyCarePath copay program before filling the first prescription, for commercially insured patients only.
• For Medicare patients, estimating total annual drug spending across all medications to understand when the annual out-of-pocket cap will be reached, since costs can drop substantially once it is.
• For uninsured patients, applying directly to Sanofi's Patient Connection program with income documentation.

Evidence boundary: what is established, what is not

Established: Alirocumab lowers LDL cholesterol substantially compared with placebo in randomized trials, and a large cardiovascular outcomes trial in post-acute-coronary-syndrome patients reported a reduction in major cardiovascular events versus placebo. Manufacturer copay assistance for commercially insured patients and federal restrictions preventing its use for Medicare beneficiaries are documented program and regulatory facts. The 2025 Medicare Part D annual out-of-pocket cap is a documented regulatory change.

Plausible but not established by the evidence in this article: That the specific dollar ranges reported by forum users represent a typical or average patient cost, given the small, self-selected nature of the samples. That prescriber office experience with prior authorization meaningfully changes approval timelines, beyond anecdotal pattern.

Not established here: Exact current list price, exact trial event rates and hazard ratios, and exact consumer review aggregate scores are not restated as verified numbers in this draft because a verified primary-source link could not be confirmed during this review. These should be checked against the primary trial publication, a current pricing database, and the manufacturer's program terms before publication.

Findings regarding the ODYSSEY OUTCOMES trial, FOURIER trial, ACC/AHA cholesterol guideline, ACC nonstatin therapy consensus pathway, and inclisiran trial referenced above reflect commonly reported results, though reported figures vary between studies and have not been independently confirmed here.